HR Execs on the Move

American Society of Dermatopathology

www.asdp.org

 
American Society of Dermatopathology is a Northbrook, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.asdp.org
  • 60 Revere Dr Ste 500
    Northbrook, IL USA 60062
  • Phone: 847.400.5820

Executives

Name Title Contact Details

Similar Companies

aTyr Pharma

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases.

Pharma BioSource Inc

Pharma BioSource Inc is a Blue Bell, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Abengoa Bioenergy Corporation

Abengoa Bioenergy Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Vysis

Vysis, Inc. is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DynamiCure

DynamiCure is employing a platform-agnostic approach to discover and develop therapeutics designed to address significant unmet medical needs in oncology and autoimmune disease. We are driven by science and passionate about advancing patient care, translating pioneering new insights on immuno-normalization into a pipeline of innovative candidates with first-in-class and best-in-class potential. Since our founding in 2019, we have identified and obtained exclusive global rights to several novel targets and are rapidly advancing into the clinic both monoclonal and bispecific therapeutic antibody candidates.